Navigation Links
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Date:10/27/2008

Duramed to Launch First Lower-Dose, Extended-Cycle Oral Contraceptive for the Prevention of Pregnancy

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for LoSEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive. LoSEASONIQUE(R) is the first lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Under the LoSEASONIQUE(R) extended-cycle regimen, women take combination tablets containing 0.10 mg levonorgestrel/0.02 mg of ethinyl estradiol daily for 84 consecutive days, followed 0.01 mg ethinyl estradiol tablets for seven days. The regimen is designed to reduce the number of withdrawal bleeding periods from 13 to four per year. By contrast, the majority of oral contraceptive products currently available in the United States are based on a regimen of 21 treatment days, followed by seven days of placebo.

LoSEASONIQUE(R) will be shipped to trade customers and available by prescription to women in the first quarter of 2009. Duramed will initiate promotion to healthcare providers in early 2009 using its sales force and other marketing initiatives.

"As a leader in women's health, Duramed is committed to continuing to develop new products that provide women a choice as they discuss birth control options with their healthcare providers," said Fred Wilkinson, Duramed's Chief Executive Officer. "We're pleased that the FDA has approved LoSEASONIQUE(R) as a safe, effective new birth control option for U.S. women." '/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
4. FDA Approves Fougeras Clotrimazole Cream USP 1%
5. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
6. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
7. Signalife Board Approves Merger
8. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
11. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... by swimming , ... Argonne, ... Department of Energy’s (DOE) Argonne National Laboratory and Northwestern University, ... when suspended in a solution, providing insights for design of ... are a million times more massive than the bacteria,” said ...
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- ... life sciences industry and an active venture capital ... Indiana State Teachers Retirement Fund, Indiana University, Purdue ... Fairbanks Foundation, and Credit Suisse today announced the ... venture capital fund of funds. ,, Organized through ...
(Date:12/16/2009)... company,s revenues increase 22% for fiscal 2009; on ... , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix Biosystems ... and biological technologies, today reported financial results for ... year ended September 30, 2009, Microbix reported revenues ... same period in 2008. For fourth-quarter 2009, the ...
(Date:12/16/2009)... Assessment with the Food and Drug Administration ... AEterna Zentaris Inc. (NASDAQ: AEZS ; ... company focused on oncology and endocrine therapy, ... Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of ... perifosine (KRX-0401), the Company,s PI3K/Akt pathway inhibitor, ...
Breaking Biology Technology:Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5
... statement,was issued today by the law firm of Schiffrin Barroway ... class action lawsuit was filed in the,United States District Court ... of securities of LCA-Vision, Inc. (Nasdaq: LCAV ) ("LCA" ... inclusive (the,"Class Period"). If you wish to discuss this ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... abstract for TRU-015 for rheumatoid arthritis (RA), ... College of Rheumatology (ACR),Annual Scientific Meeting. This ... Association of Rheumatology Health Professionals (ARHP) Annual,Scientific ...
... NAAS, Ireland, Oct. 1 A highly sensitive, ... (BVDV) was,selected as the Best New Veterinary Product ... BVDV real time PCR test was selected for ... representing,members of the global community of animal sciences ...
Other Biology Technology:Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting 2BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards 2BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards 3
(Date:12/16/2009)... REDWOOD SHORES, Calif. and PALM HARBOR, Fla., ... ("CIC") (OTC Bulletin Board: CICI), a leading ... process automation in the financial industry* and ... and Docubase Systems Inc. ("Docubase"), a leading ... announced today that they have entered an ...
(Date:12/16/2009)... Dec. 7 IgeaCare Solutions Inc. is ... of the healthcare communications company previously operating as ... will now move forward under new leadership and ... Michael Rochon to the position of Chief Executive ... focus on providing a superior servicing and support ...
(Date:12/16/2009)... Dec. 9 BIO-key International, Inc. ... finger-based biometric identification solutions, today announced that ... respected security publications, named BIO-key International the ... Access Control sub-category Biometrics. ,, (Logo: ... Stephenson, technology editor, SC Magazine, "Biometric providers ...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Canadian research breakthrough holds promise for development of effective cancer therapies 9773 1Canadian research breakthrough holds promise for development of effective cancer therapies 9773 2NOAA scientists map fish habitat and movements at Grays Reef Marine Sanctuary 9769 1NOAA scientists map fish habitat and movements at Grays Reef Marine Sanctuary 9769 2Wigix Announces 1 Million in Open Sell Orders 56065 1Wigix Announces 1 Million in Open Sell Orders 56065 2
... of a family of mysterious objects called microcompartments that ... The discovery was published Aug. 5 in the journal ... microcompartments are built, and what the pieces look like," ... biochemistry, and a member of the UCLA-DOE Institute of ...
... details of a family of mysterious objects called microcompartments ... bacteria. The discovery was published Aug. 5 in the ... how microcompartments are built, and what the pieces look ... and biochemistry, and a member of the UCLA-DOE Institute ...
... in Africa and understanding the factors affecting its transmission ... the disease. A new study published in the premier ... by Jacob Koella and colleagues now reveals that mosquitoes ... of malaria than to those infected with non-transmissible forms ...
Other Biology News:Nighttime Dying Linked To Sleep Apnea From Brain Cell Loss 2Nighttime Dying Linked To Sleep Apnea From Brain Cell Loss 3New discovery blurs distinction between human cells and those of bacteria 2New discovery blurs distinction between human cells and those of bacteria 3Mosquitoes are more attracted to individuals infected with malaria 2
Human Cell Line Slides...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: